Fas

Fas

Fas Molekülinformation

Molecule Name
Apoptosis-mediating surface antigen FAS
Molekülalias
FAS,ALPS1A,APO1,APT1,CD95,FAS1,FASTM,TNFRSF6,FasR
Drug Development Progress
Anzahl der klinischen Arzneimittel1
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
Tumor Necrosis Factor Receptor Superfamily, Member 6,Apo-1 antigen,CD95,APT1,FAS1,TNFRSF6,FAS,Fas Cell Surface Death Receptor,Fas (TNF Receptor Superfamily, Member 6),Apoptosis-Mediating Surface Antigen FAS,TNF Receptor Superfamily Member 6,FASLG Receptor,CD95 Antigen,Mutant Tumor Necrosis Receptor Superfamily Member 6,Tumor Necrosis Factor Receptor Superfamily Member 6,Apoptosis Signaling Receptor FAS,APO-1 Cell Surface Antigen,Apoptosis Antigen 1,Fas AMA,ALPS1A,APO-1,FASTM,fas Receptor
Molekülhintergrund
The Fas is also known as FAS receptor (FasR), apoptosis antigen 1 (APO-1 or APT), cluster of differentiation 95 (CD95) or tumor necrosis factor receptor superfamily member 6 (TNFRSF6). is a death receptor on the surface of cells that leads to programmed cell death (apoptosis). It is one of two apoptosis pathways, the other being the mitochondrial pathway. FasR is located on chromosome 10 in humans and 19 in mice. Similar sequences related by evolution (orthologs) are found in most mammals. Fas forms the death-inducing signaling complex (DISC) upon ligand binding. Membrane-anchored Fas ligand trimer on the surface of an adjacent cell causes trimerization of Fas receptor. This event is also mimicked by binding of an agonistic Fas antibody, though some evidence suggests that the apoptotic signal induced by the antibody is unreliable in the study of Fas signaling. To this end, several clever ways of trimerizing the antibody for in vitro research have been employed.Upon ensuing death domain (DD) aggregation, the receptor complex is internalized via the cellular endosomal machinery. This allows the adaptor molecule FADD to bind the death domain of Fas through its own death domain. Recently, Fas has also been shown to promote tumor growth, since during tumor progression, it is frequently downregulated or cells are rendered apoptosis resistant. Cancer cells in general, regardless of their Fas apoptosis sensitivity, depend on constitutive activity of Fas. This is stimulated by cancer-produced Fas ligand for optimal growth.

Fas Produktliste

Species
  • Human(2)
Tag
  • Fc Tag(1)
  • His Tag(1)
Host
  • HEK293(2)
Conjugate
  • Unconjugated(2)
Grade
  • RUO(2)
Low Endotoxin
  • No(2)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
Fas
Human Fas / TNFRSF6 / CD95 Protein, His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE

$290.00

50ug
Fas
Human Fas / TNFRSF6 / CD95 Protein, Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$295.00

100ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
XelafaslatideONL-1204Phase 2 ClinicalOnl Therapeutics
Geographic Atrophy; Glaucoma, Open-Angle; Macular Degeneration; Retinal Detachment
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
KanglaiteApprovedZhejiang Kanglaite Pharmaceutical Co LtdKanglaiteMainland ChinaLiver Neoplasms; Carcinoma, Non-Small-Cell LungZhejiang Kanglaite Pharmaceutical Co Ltd1997-01-01
Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours
Details
Customer Reviews